TUKYSA® is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or MBC who have received at least 2 prior anti-HER2 treatment regimens.¹

Combine TUKYSA and capecitabine oral therapies with either intravenous or subcutaneous trastuzumab, allowing choice for treatment at hospital, in clinic or at home

For more information about co-administered trastuzumab and capecitabine, please refer to the respective Summary of Product Characteristics.

• Treatment with TUKYSA combination therapy (tucatinib + trastuzumab + capecitabine) should be continued until disease progression or unacceptable toxicity¹
• No dose adjustment is required in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment (Child-Pugh C), a reduced starting dose of 200 mg TUKYSA orally twice daily is recommended¹
• Concomitant use with strong CYP2C8 inhibitors should be avoided. If coadministration with a strong CYP2C8 inhibitor cannot be avoided, the starting TUKYSA dose should be reduced to 100 mg orally, twice daily. After discontinuation of the strong CYP2C8 inhibitor for 3 elimination half-lives, the TUKYSA dose that was taken prior to initiating the inhibitor should be resumed¹
• TUKYSA should be taken approximately 12 hours apart, at the same time every day, with or without a meal¹
• TUKYSA may be taken at the same time with capecitabine¹
• Tablets should be swallowed whole and not chewed, crushed or split prior to swallowing¹
• In the case of a missed dose, the patient should take their next dose at the regularly scheduled time¹
• No dose adjustment is required in patients with mild, moderate, or severe renal impairment or patients ≥ 65 years. Not studied in patients over 80 years old.

TUKYSA should be permanently discontinued in patients unable to tolerate 150 mg orally, twice daily

Please refer to the TUKYSA Summary of Product Characteristics for full information on dose monitoring and guidance on the management of adverse events.

Please refer to the respective Summary of Product Characteristics for trastuzumab and capecitabine for dose modifications for toxicities suspected to be caused by those therapies.

*Grades based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03.¹
†Prompt medical management should also be instituted in the event of persistence of concomitant Grade 2 diarrhoea with concomitant Grade >2 nausea and/or vomiting.¹

Please refer to the TUKYSA Summary of Product Characteristics for full information on dose monitoring and guidance on the management of adverse events.
Please refer to the respective Summary of Product Characteristics for trastuzumab and capecitabine for dose modifications for toxicities suspected to be caused by those therapies.

Please refer to the TUKYSA Summary of Product Characteristics
for full information

• TUKYSA does not require any special storage conditions¹
• Shelf life: 2 years;¹ do not use this medicine after the expiry date which is stated on the blister and the carton. The expiry date refers to the last day of that month

ALT: Alanine Aminotransferase, AST: Aspartate Aminotransferase; MBC: Metastatic Breast Cancer; ULN, upper limit of normal.

References:

1. TUKYSA Summary of Product Characteristics for the United Kingdom click here.
2. TUKYSA  Patient Information Leaflet click here.